Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
NCT03065023
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class
Stopped
Group B not started for business reasons.
Conditions
Advanced Solid Tumors
Interventions
DRUG:
MK-4621
Sponsor
Merck Sharp & Dohme LLC